Clinical Efficacy and Safety of Sericin Hydrogel Sheet Impregnated With Bird's Nest Extract
20 september 2021 uppdaterad av: Pornanong Aramwit, Pharm.D., Ph.D, Chulalongkorn University
Clinical Efficacy and Safety of Sericin Hydrogel Sheet Impregnated With Bird's Nest Extract in Prevention of Hypertrophic Scar Development at Split-thickness Skin Graft Donor Site
Split-thickness skin graft (STSG) is one of the most common procedures performed in plastic surgery and dermatology.
The donor site of skin grafting is expected to heal without scarring.
However, hypertrophic scar formation is prevalent among STSG donor sites during scar maturation and has become a significant problem at present.
Hypertrophic scar results in aesthetic, physical, functional, and psychological problems, leading to a dramatic impact on patients' quality of life ultimately.
There are many current therapeutic approaches for preventing and treating hypertrophic scars; however, they remain clinically unsatisfactory because many treatments have been associated with high recurrent rates, high cost, and side effects.
Currently, there are no gold standards for hypertrophic scar therapy.
There are many attempts to develop new treatment options for the prevention and management of scarring that are acceptable to both physicians and patients.
It has previously been shown that both edible bird's nest (EBN) extract and sericin have effectiveness in reducing scar development.
They might be a suitable alternative option for scar prevention and could be used safely.
Therefore, the sericin hydrogel sheet impregnated with EBN extract is developed as it is believed that the synergism of these combined compounds would be a great help to prevent the development of scars.
This study aims to evaluate the efficacy and safety of sericin hydrogel sheet impregnated with EBN extract for the prevention of scar formation in patients with STSG donor sites.
Studieöversikt
Status
Har inte rekryterat ännu
Intervention / Behandling
Detaljerad beskrivning
Prospective, randomized, single-center, double-blinded, placebo-controlled, matched pairs clinical study will be conducted to investigate the efficacy and safety of sericin hydrogel sheet impregnated with EBN extract for the prevention of scar development at STSG donor site.
Patients who underwent the STSG procedure at the Division of Plastic and Reconstructive Surgery, Department of Surgery, King Chulalongkorn Memorial Hospital will be considered for inclusion and exclusion criteria.
Thirty patients will be enrolled in this study.
After complete epithelialization, each donor site will be equally divided into two halves: upper and lower halves.
Both halves of the donor site will be randomized into sericin hydrogel sheet impregnated with EBN extract group (treatment group) or placebo hydrogel sheet group (control group).
The application of both dressings will be done once daily by the patient in the morning or evening after shower.
Both dressings will be recommended to wear over the donor site for 8-12 hours per day.
The duration of treatment will be six months.
Wound quality at 1, 2, 4, and 6 months after starting application will be measured in terms of erythema level, melanin level, transepidermal water loss by using Cutometer® and scar quality (Vancouver scar scale as well as Patient and Observer Scar Assessment Scale).
Adverse reactions will also be evaluated.
Studietyp
Interventionell
Inskrivning (Förväntat)
30
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Pornanong Aramwit, Ph.D
- Telefonnummer: +66899217255
- E-post: aramwit@gmail.com
Studieorter
-
-
-
Bangkok, Thailand, 10330
- King Chulalongkorn Memorial Hospital
-
Kontakt:
- Pornanong Aramwit, Ph.D
- Telefonnummer: +66899217255
- E-post: aramwit@gmail.com
-
Huvudutredare:
- Pornanong Aramwit, Ph.D
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 65 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- STSG donor sites freshly closed not more than 1 month after completed epithelialization
- STSG donor sites are at least 5 x 10 cm2 in size.
- STSG donor sites are located on the thigh.
- Donor sites have not been used previously for skin graft harvesting.
- Aged 18-65 years
- Patients who can read and write Thai language
- Willingness to participate
- Signed consent form
Exclusion Criteria:
- Patients with critical illness (such as systemic infection), major acute illness, or chronic medical illness associated with delayed wound healing (such as poor-controlled diabetes mellitus, end-stage renal disease (ESRD), cancer, or immunocompromised diseases)
- Patients with mental disorder
- Patients with active dermatologic conditions such as contractive skin disorders (e.g., scleroderma), psoriasis, or atopic dermatitis
- After completed epithelialization, patients who used other topical agents or dressings on STSG donor sites within 14 days prior to enrollment
- Known sensitivity or allergy to sericin, EBN, other constituents in hydrogel sheet, or adhesive tape
- Pregnancy
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Sericin hydrogel sheet impregnated with EBN extract
Apply sericin hydrogel sheet impregnated with EBN extract on one-half of the donor site once daily for 8-12 hours per day for 6 months.
|
Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site.
Then, the donor site will be covered with adhesive tape (secondary dressing).
The application of primary and secondary dressings will be done once daily after shower in the morning or evening.
Both dressings will be recommended to wear over the donor site for 8-12 hours per day.
Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day.
The duration of the dressing application will be 6 months.
|
|
Placebo-jämförare: Placebo hydrogel sheet
Apply placebo hydrogel sheet on another half of the donor site once daily for 8-12 hours per day for 6 months.
|
Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site.
Then, the donor site will be covered with adhesive tape (secondary dressing).
The application of primary and secondary dressings will be done once daily after shower in the morning or evening.
Both dressings will be recommended to wear over the donor site for 8-12 hours per day.
Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day.
The duration of the dressing application will be 6 months.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Vancouver Scar Scale (VSS) score
Tidsram: 6 months
|
Clinicians will evaluate scar quality using VSS at 6 months after commencing the dressing application.
The range of score is 0 to 10. Higher scores mean a worse outcome.
|
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Patient and Observer Scar Assessment Scale (POSAS) score
Tidsram: 6 months
|
Clinicians will evaluate scar quality using POSAS at 1, 2, 4, and 6 months after commencing the dressing application.
The range of score is 1 to 10. Normal skin will be recorded as scale 1.
Higher scores mean a worse outcome.
|
6 months
|
|
Melanin level
Tidsram: 6 months
|
Melanin level will be measured using Cutometer® with mexameter mode at 1, 2, 4, and 6 months after commencing the dressing application.
|
6 months
|
|
Erythema level
Tidsram: 6 months
|
Erythema level will be measured using Cutometer® with mexameter mode at 1, 2, 4, and 6 months after commencing the dressing application.
|
6 months
|
|
Transepidermal water loss (TEWL)
Tidsram: 6 months
|
TEWL will be measured using Cutometer® with tewameter mode at 1, 2, 4, and 6 months after commencing the dressing application.
|
6 months
|
|
Adverse events
Tidsram: 6 months
|
Adverse events resulted from dressing application will be evaluated.
|
6 months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Pornanong Aramwit, Ph.D, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Förväntat)
1 november 2021
Primärt slutförande (Förväntat)
31 oktober 2022
Avslutad studie (Förväntat)
31 oktober 2022
Studieregistreringsdatum
Först inskickad
3 augusti 2021
Först inskickad som uppfyllde QC-kriterierna
3 augusti 2021
Första postat (Faktisk)
10 augusti 2021
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
24 september 2021
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
20 september 2021
Senast verifierad
1 september 2021
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Med Chula IRB 572/64
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Sår
-
HealthpointAvslutadUppföljning av Acute Wound Scar StudyFörenta staterna